Recent results from targeted alpha therapy show that this type of cancer treatment is exceptionally potent for treatment of cancer types which are either in micro-metastases or as small tumours. By incorporating the highly-destructive alpha-radiation to bio-chemicals that specifically target and attach themselves to cancerous cells, the alpha-radiation is deposited specifically in and around the cancerous cell. The race is therefore on to produce alpha-emitters in sufficient quantities and to attach these to the most efficient targeting bio-chemicals. The present partnership between York and the Life Sciences Division at TRIUMF, Canada, combines the necessary expertise to make a step-change in the technologies available for optimisation and quality control of the development of new alpha treatments, thereby accelerating this development.
|Effective start/end date||1/12/18 → 15/11/19|